176 related articles for article (PubMed ID: 26762852)
1. Comparative analyses of the proteins from Mycobacterium tuberculosis and human genomes: Identification of potential tuberculosis drug targets.
Sridhar S; Dash P; Guruprasad K
Gene; 2016 Mar; 579(1):69-74. PubMed ID: 26762852
[TBL] [Abstract][Full Text] [Related]
2. Novel targets in M. tuberculosis: search for new drugs.
Lamichhane G
Trends Mol Med; 2011 Jan; 17(1):25-33. PubMed ID: 21071272
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. In silico analyses for the discovery of tuberculosis drug targets.
Chung BK; Dick T; Lee DY
J Antimicrob Chemother; 2013 Dec; 68(12):2701-9. PubMed ID: 23838951
[TBL] [Abstract][Full Text] [Related]
5. Recognizing drug targets using evolutionary information: implications for repurposing FDA-approved drugs against Mycobacterium tuberculosis H37Rv.
Ramakrishnan G; Chandra NR; Srinivasan N
Mol Biosyst; 2015 Dec; 11(12):3316-31. PubMed ID: 26429199
[TBL] [Abstract][Full Text] [Related]
6. Modulators targeting protein-protein interactions in Mycobacterium tuberculosis.
Luo G; Ming T; Yang L; He L; Tao T; Wang Y
Microbiol Res; 2024 Jul; 284():127675. PubMed ID: 38636239
[TBL] [Abstract][Full Text] [Related]
7. Purification and characterization of anthranilate synthase component I (TrpE) from Mycobacterium tuberculosis H37Rv.
Lin X; Xu S; Yang Y; Wu J; Wang H; Shen H; Wang H
Protein Expr Purif; 2009 Mar; 64(1):8-15. PubMed ID: 18952181
[TBL] [Abstract][Full Text] [Related]
8. Mycobacterium sulfur metabolism and implications for novel drug targets.
Zeng L; Shi T; Zhao Q; Xie J
Cell Biochem Biophys; 2013 Mar; 65(2):77-83. PubMed ID: 23054909
[TBL] [Abstract][Full Text] [Related]
9. A whole genome bioinformatic approach to determine potential latent phase specific targets in Mycobacterium tuberculosis.
Defelipe LA; Do Porto DF; Pereira Ramos PI; Nicolás MF; Sosa E; Radusky L; Lanzarotti E; Turjanski AG; Marti MA
Tuberculosis (Edinb); 2016 Mar; 97():181-92. PubMed ID: 26791267
[TBL] [Abstract][Full Text] [Related]
10.
Sawicki R; Ginalska G
Future Med Chem; 2019 Aug; 11(16):2193-2203. PubMed ID: 31538522
[TBL] [Abstract][Full Text] [Related]
11. Increasing the structural coverage of tuberculosis drug targets.
Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
[TBL] [Abstract][Full Text] [Related]
12. The potential impact of structural genomics on tuberculosis drug discovery.
Arcus VL; Lott JS; Johnston JM; Baker EN
Drug Discov Today; 2006 Jan; 11(1-2):28-34. PubMed ID: 16478688
[TBL] [Abstract][Full Text] [Related]
13. Unraveling the potential of intrinsically disordered proteins as drug targets: application to Mycobacterium tuberculosis.
Anurag M; Dash D
Mol Biosyst; 2009 Dec; 5(12):1752-7. PubMed ID: 19763328
[TBL] [Abstract][Full Text] [Related]
14. The Mycobacterium tuberculosis drugome and its polypharmacological implications.
Kinnings SL; Xie L; Fung KH; Jackson RM; Xie L; Bourne PE
PLoS Comput Biol; 2010 Nov; 6(11):e1000976. PubMed ID: 21079673
[TBL] [Abstract][Full Text] [Related]
15. Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics.
Fang Z; van der Merwe RG; Warren RM; Schubert WD; Gey van Pittius NC
Tuberculosis (Edinb); 2015 Mar; 95(2):131-6. PubMed ID: 25578513
[TBL] [Abstract][Full Text] [Related]
16. Flux balance analysis of mycolic acid pathway: targets for anti-tubercular drugs.
Raman K; Rajagopalan P; Chandra N
PLoS Comput Biol; 2005 Oct; 1(5):e46. PubMed ID: 16261191
[TBL] [Abstract][Full Text] [Related]
17.
Nunes JES; Duque MA; de Freitas TF; Galina L; Timmers LFSM; Bizarro CV; Machado P; Basso LA; Ducati RG
Molecules; 2020 Mar; 25(6):. PubMed ID: 32168746
[TBL] [Abstract][Full Text] [Related]
18. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
19. Drug discovery in tuberculosis: a molecular approach.
Mitra PP
Indian J Tuberc; 2012 Oct; 59(4):194-206. PubMed ID: 23342539
[TBL] [Abstract][Full Text] [Related]
20. Exploring optimal drug targets through subtractive proteomics analysis and pangenomic insights for tailored drug design in tuberculosis.
Khan MF; Ali A; Rehman HM; Noor Khan S; Hammad HM; Waseem M; Wu Y; Clark TG; Jabbar A
Sci Rep; 2024 May; 14(1):10904. PubMed ID: 38740859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
